Stock ABBOTINDIA ABBOTT INDIA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Abbott India Limited NSE India S.E.

Equities

ABBOTINDIA

INE358A01014

Pharmaceuticals

Delayed NSE India S.E.
Other stock markets
 01:20:24 16/05/2024 pm IST 		5-day change 1st Jan Change
26,403 INR -0.03% Intraday chart for Abbott India Limited +3.29% +15.54%
10/05 Abbott India's Net Profit Climbs in Fiscal Q4; Shares Up 3% MT
09/05 Drugmaker Abbott India posts Q4 profit rise on higher sales RE

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,55,053 3,28,419 3,18,498 3,76,101 4,69,324 5,61,708 - -
Enterprise Value (EV) 1 1,55,053 3,06,445 2,94,408 3,48,609 4,49,953 5,72,584 5,40,243 5,34,387
P/E ratio 34.4 x 55.4 x 46.1 x 47.1 x 49.4 x 47.7 x 42.8 x 36.7 x
Yield 0.69% 0.69% 0.8% 0.82% 0.81% 1.11% 1.35% 1.45%
Capitalization / Revenue 4.21 x 8.02 x 7.39 x 7.65 x 8.77 x 9.79 x 8.68 x 7.83 x
EV / Revenue 4.21 x 7.49 x 6.83 x 7.09 x 8.41 x 9.79 x 8.35 x 7.45 x
EV / EBITDA 25.6 x 40.5 x 32 x 32 x 37.3 x 39.4 x 33.2 x 28.6 x
EV / FCF 31.9 x 50.2 x 41.9 x 38.6 x 52.4 x 51.5 x 38.3 x 38 x
FCF Yield 3.14% 1.99% 2.39% 2.59% 1.91% 1.94% 2.61% 2.63%
Price to Book 7.72 x 13.5 x 12.2 x 13.3 x 14.7 x 15.1 x 13.7 x 11.4 x
Nbr of stocks (in thousands) 21,249 21,249 21,249 21,249 21,249 21,249 - -
Reference price 2 7,297 15,456 14,989 17,699 22,087 26,434 26,434 26,434
Announcement Date 27/05/19 08/06/20 18/05/21 17/05/22 19/05/23 09/05/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 36,786 40,931 43,100 49,193 53,487 58,489 64,696 71,740
EBITDA 1 6,067 7,564 9,215 10,877 12,056 14,531 16,283 18,674
EBIT 1 5,898 6,968 8,633 10,216 11,357 13,819 16,284 18,541
Operating Margin 16.03% 17.02% 20.03% 20.77% 21.23% 23.63% 25.17% 25.85%
Earnings before Tax (EBT) 1 6,988 8,027 9,260 10,797 12,738 16,178 17,482 20,323
Net income 1 4,503 5,929 6,907 7,987 9,494 12,012 13,121 15,137
Net margin 12.24% 14.49% 16.03% 16.24% 17.75% 20.54% 20.28% 21.1%
EPS 2 211.9 279.0 325.0 375.9 446.8 565.3 617.5 720.2
Free Cash Flow 1 4,868 6,104 7,034 9,036 8,593 10,469 14,107 14,050
FCF margin 13.23% 14.91% 16.32% 18.37% 16.07% 17.77% 21.8% 19.59%
FCF Conversion (EBITDA) 80.24% 80.69% 76.34% 83.07% 71.27% 69.7% 86.63% 75.24%
FCF Conversion (Net income) 108.1% 102.94% 101.84% 113.13% 90.51% 88.13% 107.51% 92.82%
Dividend per Share 2 50.00 107.0 120.0 145.0 180.0 293.2 358.0 384.3
Announcement Date 27/05/19 08/06/20 18/05/21 17/05/22 19/05/23 09/05/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 10,954 10,955 12,178 12,221 12,244 12,550 13,044 13,795 13,265 13,431 14,790 15,042 14,995 14,696
EBITDA 1 2,418 2,055 2,652 2,597 2,691 2,938 2,704 3,433 3,165 2,801 3,550 3,581 3,658 3,640
EBIT - - - - - - - - 2,987 - - - 3,368 3,654
Operating Margin - - - - - - - - 22.52% - - - 22.46% 24.86%
Earnings before Tax (EBT) - - - - - - - - - - - - - -
Net income 1 1,771 1,525 1,958 1,923 1,992 2,114 2,056 2,655 2,468 2,314 2,902 2,854 3,044 2,859
Net margin 16.17% 13.92% 16.07% 15.74% 16.27% 16.85% 15.77% 19.25% 18.61% 17.23% 19.62% 18.97% 20.3% 19.45%
EPS 83.36 - - 90.51 93.74 99.49 96.77 125.0 116.2 - - - 137.4 142.5
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 09/02/21 18/05/21 06/08/21 12/11/21 09/02/22 17/05/22 10/08/22 14/11/22 10/02/23 19/05/23 09/08/23 - - -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - 21,974 24,090 27,492 19,371 22,660 21,466 27,322
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 4,868 6,104 7,034 9,036 8,593 10,469 14,107 14,051
ROE (net income / shareholders' equity) 24.3% 26.7% 27.4% 29.5% 31.6% 33.7% 33.6% 33.3%
ROA (Net income/ Total Assets) - 19.9% 18.7% 19.8% 21.6% 23.1% 23.1% 23.5%
Assets 1 - 29,828 36,936 40,322 43,898 51,431 56,880 64,499
Book Value Per Share 2 945.0 1,144 1,225 1,327 1,500 1,750 1,931 2,315
Cash Flow per Share 2 - 295.0 342.0 446.0 420.0 433.0 297.0 597.0
Capex 1 123 157 233 441 341 542 574 576
Capex / Sales 0.33% 0.38% 0.54% 0.9% 0.64% 0.92% 0.89% 0.8%
Announcement Date 27/05/19 08/06/20 18/05/21 17/05/22 19/05/23 09/05/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Abbott India Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+35.01% 709B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.74% 595B
JOHNSON & JOHNSON Stock Johnson & Johnson
-2.60% 367B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.83% 334B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 289B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.36% 239B
NOVARTIS AG Stock Novartis AG
+9.31% 211B
ROCHE HOLDING AG Stock Roche Holding AG
-3.44% 203B
AMGEN INC. Stock Amgen Inc.
+10.77% 171B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ABBOTINDIA Stock
  4. ABBOTINDIA Stock
  5. Financials Abbott India Limited
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**BENEFIT NOW**0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW